VEROPHARM Announces Preliminary Results for First Nine Months of 2011
OREANDA-NEWS. December 28, 2011. "VEROPHARM" [RTS:VRPH, MICEX:VFRM] announces preliminary data and operational performance indicators for the first nine months of 2011 year according to the management accounting.
Sales
In 9М 2011 sales of Veropharm’s finished goods increased by 15,3% compared to the same period in 2010, reaching RUR 4,534.1 million.[1]
Rx drugs sales amounted to RUR 3,184.4 million in 9M
OTC drugs sales amounted to RUR 578.7 million in 9M
In 9M 2011 traditional drug sales amounted to RUR 22.5 million, which represents 55,1% decrease as compared to 9M 2010, and made up 0,5% of total finished goods sales.
Group of non-pharmaceutical products
Adhesive bandages and cosmetic products sales came to RUR 748.5 million, a 17,2% increase in comparison with 9M 2010. The share of adhesive bandages and cosmetic products in total finished goods sales of the Company was 16,5%.
Veropharm sales as part of the Federal Reimbursement Program (FRP) came to RUR 102,7 million, accounting for 2,3% of the Company’s total finished goods sales.[2]
In 9M 2011 sales in
RX drugs segment
Total sales of the five most popular prescription drugs by the results in 9M 2011 amounted to RUR 1,146.1 million, or 36% of sales in the prescription drugs segment and 25% of the Company’s total finished goods sales.[2]
The five top-selling Rx drugs in 9M 2011 results include:
Cerepro (Holina Alfostserat; ATC "Central nervous system"); sales growth in comparison with 9M 2010 amounted 38%; 9% of sales in the prescription drugs segment;
Irunine (Itraconazole; ATC[3] "General anti-infectives systemic"); sales growth in comparison with 9M 2010 amounted 53%; 8% of sales in the prescription drugs segment;
Geptor (Ademetionine; ATC"Digestive tract and metabolism"); sales growth in comparison with 9M 2010 amounted 34%; 7% of sales in the prescription drugs segment;
Amigrenin (Sumatriptan; ATC "Central nervous system"); sales growth in comparison with 9M 2010 amounted 192%; 6% of sales in the prescription drugs segment;
Paclitaxel-LENS (Paclitaxel; ATC "Antineoplastic and immunomodulating agents"); 6% of sales in the prescription drugs segment;
OTC drugs segment
Total sales of the five products in the OTC drugs segment amounted to 99% of sales in the OTC drugs segment.
Xilen (Xylometazoline; ATC "Respiratory system"); sales growth in comparison with 9M 2010 amounted 17%; 51% of sales in the OTC drugs segment;
Slabilen (Sodium picosulfate; ATC "Alimentary tract and metabolism"); sales growth in comparison with 9M 2010 amounted 18%; 28% of sales in the OTC drugs segment;
Motilak (Domperidone; ATC "Alimentary tract and metabolism"); sales growth in comparison with 9M 2010 amounted 13%; 15% of sales in the OTC drugs segment;
Vitasharm and Vitatress (ATC "Vitamins"); sales growth in comparison with 9M 2011 amounted 92%; 4% of sales in the OTC drugs segment;
Ginecotex vaginal tablets (Benzalkonium chloride; ATC "Urinary system&sex hormone"); 1% of sales in the OTC drugs segment.
Traditional drugs segment
Total sales of the five most popular traditional drugs by the results in 9M 2011 amounted to RUR 21,9 million, or 98% of sales in the traditional drugs segment.
The five top-selling traditional drugs for 9M 2011 include
Vero-Dexamethasone (Dexamethasone; ATC "Hormonal drugs"); 51% of sales in the traditional drugs segment;
Pyridoxine hydrochloride (Pyridoxine; ATC "Alimentary tract and metabolism"); 23% of sales in the traditional drugs segment;
Vero-Ciprofloxacin (Ciprofloxacin; ATC "General anti-infective systemic"); 13% of sales in the traditional drugs segment;
Fluconazole (Fluconazole; ATC "General anti-infective systemic"); 9% of sales in the traditional drugs segment;
Drotaverine (Drotaverine; ATC "Alimentary tract and metabolism"); 2% of sales in the traditional drugs segment.
Adhesive bandages and cosmetic products segment
In 9M 2011 segment of Adhesive bandages and Cosmetic products had the following structure:
Conventional bacterial adhesive bandages; 46% of sales in segment in 9M 2011;
Conventional reel adhesive bandages; 23% of sales in the segment in 9M 2011;
Therapeutic patches - pepper plasters, 15% of sales in the segment in 9M 2011;
Therapeutic patches - corn plasters, 15% of sales in the segment in 9M 2011;
Cosmetic products (Veromistin Silver, Daily,
New drugs production and sales
During the first nine mounths of 2011 Veropharm launched production and sales of the following new drugs:
Vero-Netilmicin (Netilmicin; ATC "Antiinfectives for systemic use");
Vero-Asparaginase (Asparaginase; АТС "Antineoplastic and immunomodulating agents"); new dosage – 10 000 ME №10;
Veroklast (Zoledronic acid; ATC "Musculoskeletal system"); new dosage – 4mg/5 ml 5ml №1;
Veromistin Silver (Myramistin; Remedy for intimate hygiene); new dosage – 50ml №1;
Veromistin Daily (Myramistin; Remedy for hygienic treatment of the skin of hands and feet); new dosage – 50ml №1;
Veromistin Flores (Myramistin; Remedy for oral hygiene); new dosage – 50ml №1;
Mielastra (Filgrastim; АТС "Antineoplastic and immunomodulating agents").
New drugs registration
In the first nine mounths of 2011 received registration certificate for the following products:
Poludan (Polyadenilic acid + Polyuridilic acid; АТС "Sensory organs"); new form and dosage - nasal drops 50 unit/ml;
Aproteks (Aprotinin; ATC "Blood & blood forming organs"); new dosage -10000 KIE/ml;
Xilen (Xylometazoline; ATC "Respiratory system"); new form - nasal spray;
The bandage Uniplast ointment;
The bandage Uniplast wound sorbent;
Additionally, 5 drugs are currently at different stages of the registration process.
Debt
At the end of 9M 2011 Veropharm’s debt came to RUR 979.1 million, that represents less than 20% of net assets.
[1] according to management accounts of OJSC “Veropharm”
[2] % - percent of finished goods sales
[3] ATC – anatomico-therapeutico-chemical group
Комментарии